RESUMEN
Introduction: Ovarian cancer is the most lethal gynecologic cancer, whose high mortality rate is partly due to late diagnosis. Tumor-specific markers that can be detected in early stages of the disease could probably improve treatment results. In this study, we evaluated the diagnostic value of serum levels of osteopontin in patients with epithelial ovarian tumors
Patients and methods: Twenty five patients with ovarian cancer and 25 patients with pelvic masses and 25 healthy women were enrolled in this study. Blood samples were taken from the patients from the first two groups before surgery and the healthy controls donated blood at the same time. Osteopontin serum level was measured by Enzyme-Linked Immunosorbent Assay method using human osteopontin enzyme immunoassay kits. Finally osteopontin levels before surgery were compared between groups
Results: The mean age in patients with ovarian cancer, benign tumor and normal group were 35.1, 32.4 and 31.6 years respectively. The most prevalent clinical symptom in almost half of patients with either benign or malignant pathology was abdominal pain. The average level of CA125 and osteopontin in ovarian cancer patients was 1818.4 and 9.6, respectively. The average level of CA125 and osteopontin in epithelial ovarian tumors was significantly higher than other groups. Significant linear relationship was detected between CA125 and osteopontin
Conclusion: Our study results support the fact that commitment measurement of osteopontin and CA125- due to their significant increase among the ovarian cancer patients- could be helpful in early detection of ovarian cancer
RESUMEN
Thyroid cancer is the most common cancer of endocrine system. Clinical, pathological and therapeutic factors affected patients' outcome with differentiated thyroid carcinoma. To evaluation the effective clinicopathologic factors on patients outcome with well differentiated thyroid carcinoma. In this retrospective analytic-descriptive study. Patients' files with thyroid carcinoma who referred to radiology and oncology ward in Omid and Ghaem hospital of Mashhad were assessed from 1996-2006. Cases with pathologic report of papillary and follicular carcinoma were considered and a specific questionnaire include age, sex, accepted time, pathologic subtype, tumor size and metastases, adjuvant treatment, last follow time, recurrence time, patient condition in the end refer and death time was recorded. The patients' mean age was 50.14 and median age was 52 years. 66 patients [85.7%] had papillary and 11 cases [14.3%] had follicular carcinoma. End condition in 43 cases [55.8%] was good and in 34 cases [44.2%] was bad. Mean survival time was 44.1 and median survival time was 36 months. There was a meaningful correlation between T stage with end condition [P=0.037] but there was no meaningful correlation between N stage with end condition [P=0.665]. Metastases in the first reference time had a clear correlation with patients' outcome. 41 patients [59.4%] from 69 cases with MO disease had a good end condition, against only one patient [16.7%] from 6 cases with Ml had a good outcome [P<0.001]. Also there was a meaningful correlation between patients' outcome and clinical stage [P=0.075]. None of the adjuvant treatment included iodine therapy [P=0.36], hormone therapy [P=0.378], chemotherapy and radiotherapy affected patients outcome. According to this study, factors with influence on patient's outcome with differentiated thyroid carcinoma were tumor stage, metastases in the first reference and clinical tumor stage. Lymph node involvement and adjuvant treatment had no effect on patients' prognosis